Trial · NCT00544115

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

NCT00544115, Phase 2, Active not recruiting, City of Hope Medical Center; results first posted 2023-05-10

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders. Trials, record NCT00544115. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00544115

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
NCT number: NCT00544115
Status: Active not recruiting
Phases: Phase 2
Enrollment: 260 participants, actual
Lead sponsor: City of Hope Medical Center
Conditions: Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Precancerous/Nonmalignant Condition
Interventions: busulfan, cyclophosphamide, cyclosporine, etoposide, fludarabine phosphate, melphalan, methotrexate, mycophenolate mofetil, sirolimus, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation
First posted: 2007-10-16
Last updated: 2026-06-02
Results first posted: 2023-05-10

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Neutrophil Engraftment - The Days Till ANC Recovery	Up to 180 days post transplant	The primary engraftment endpoint, neutrophil engraftment, is defined as the first of three consecutive days on which the absolute neutrophil count is \> 500/µL. The duration and extent of neutrophil engraftment is the time from transplant to neutrophil engraftment.
Secondary	Two-year Overall Survival	Up to 2 years post transplant	Overall survival (OS) was measured from peripheral stem cell infusion to death from any cause. It was estimated using the Kaplan-Meier method; the 95% confidence interval was calculated using Greenwood's formula. Participants were followed up to 2 years after transplant and Kaplan-Meier survival analysis was used to generate the two-year Overall Survival estimate presented.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Neutrophil Engraftment - The Days Till ANC Recovery	Up to 180 days post transplant	Some patients had engraftment failure and some had missing data. Therefore, the overall number of participants analyzed in each regimen is less than the overall number in the Participant Flow module.	days	MEDIAN
SECONDARY	Two-year Overall Survival	Up to 2 years post transplant	1 subject in Regimen II did not have transplant.	percentage of survival probability	NUMBER

Source ClinicalTrials.gov

Results by group12

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Neutrophil Engraftment - The Days Till ANC Recovery	Regimen I	17	95% Confidence Interval 11 to 39	days
Neutrophil Engraftment - The Days Till ANC Recovery	Regimen II	16	95% Confidence Interval 13 to 21	days
Neutrophil Engraftment - The Days Till ANC Recovery	Regimen III	15	95% Confidence Interval 8 to 36	days
Neutrophil Engraftment - The Days Till ANC Recovery	Regimen IV	14	95% Confidence Interval 14 to 17	days
Neutrophil Engraftment - The Days Till ANC Recovery	Regimen V	18	95% Confidence Interval 11 to 28	days
Neutrophil Engraftment - The Days Till ANC Recovery	Regimen VI	16	95% Confidence Interval 16 to 16	days
Two-year Overall Survival	Regimen I	58	95% Confidence Interval 45 to 69	percentage of survival probability
Two-year Overall Survival	Regimen II	50	95% Confidence Interval 25 to 71	percentage of survival probability
Two-year Overall Survival	Regimen III	54	95% Confidence Interval 45 to 62	percentage of survival probability
Two-year Overall Survival	Regimen IV	50	95% Confidence Interval 6 to 84	percentage of survival probability

1 to 10 of 12Source ClinicalTrials.gov

See all 12 results by group

Participant flow18

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Regimen I	62
Overall Study	STARTED	Regimen II	17
Overall Study	STARTED	Regimen III	130
Overall Study	STARTED	Regimen IV	4
Overall Study	STARTED	Regimen V	40
Overall Study	STARTED	Regimen VI	2
Overall Study	COMPLETED	Regimen I	62
Overall Study	COMPLETED	Regimen II	17
Overall Study	COMPLETED	Regimen III	130
Overall Study	COMPLETED	Regimen IV	4

1 to 10 of 18Source ClinicalTrials.gov

See all 18 participant flow

Adverse events1,386

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Bone marrow cellularity	Blood and lymphatic system disorders	Regimen I	1	62	1
other	Bone marrow cellularity	Blood and lymphatic system disorders	Regimen II	0	17	0
other	Bone marrow cellularity	Blood and lymphatic system disorders	Regimen III	1	130	1
other	Bone marrow cellularity	Blood and lymphatic system disorders	Regimen IV	0	4	0
other	Bone marrow cellularity	Blood and lymphatic system disorders	Regimen V	0	40	0
other	Bone marrow cellularity	Blood and lymphatic system disorders	Regimen VI	0	2	0
other	Coagulation - Other (Specify, __)	Blood and lymphatic system disorders	Regimen I	0	62	0
other	Coagulation - Other (Specify, __)	Blood and lymphatic system disorders	Regimen II	0	17	0
other	Coagulation - Other (Specify, __)	Blood and lymphatic system disorders	Regimen III	1	130	1
other	Coagulation - Other (Specify, __)	Blood and lymphatic system disorders	Regimen IV	0	4	0

1 to 10 of 1,386Source ClinicalTrials.gov

See all 1,386 adverse events

Adverse event totals18

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Regimen I	45	62
Total, all-cause mortality	Regimen II	14	17
Total, all-cause mortality	Regimen III	103	130
Total, all-cause mortality	Regimen IV	2	4
Total, all-cause mortality	Regimen V	32	40
Total, all-cause mortality	Regimen VI	1	2
Total, other adverse events	Regimen I	14	62
Total, other adverse events	Regimen II	4	17
Total, other adverse events	Regimen III	38	130
Total, other adverse events	Regimen IV	0	4

1 to 10 of 18Source ClinicalTrials.gov

See all 18 adverse event totals

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
P30CA033572	Cancer Center Support Grant	CARPTEN, JOHN D.	BECKMAN RESEARCH INSTITUTE/CITY OF HOPE	NATIONAL CANCER INSTITUTE	1985 to 2025

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00544115

GET https://conductscience.org/api/trials/v1/NCT00544115/events?page=2

API reference For AI assistants